Literature DB >> 8098553

A strategy for prophylactic vaccination against HIV.

J Salk1, P A Bretscher, P L Salk, M Clerici, G M Shearer.   

Abstract

Mesh：

Substances：

Year:  1993        PMID： 8098553     DOI： 10.1126/science.8098553

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  34 in total

1.  Cross-reactive T-cell proliferative responses to V3 peptides corresponding to different geographical HIV-1 isolates in HIV-seropositive individuals.

Authors:  P N Nehete; P C Johnson; S J Schapiro; R B Arlinghaus; K J Sastry
Journal:  J Clin Immunol       Date:  1996-03       Impact factor: 8.317

2.  HIV-1-specific cell-mediated immune responses induced by DNA vaccination were enhanced by mannan-coated liposomes and inhibited by anti-interferon-gamma antibody.

Authors:  S Toda; N Ishii; E Okada; K I Kusakabe; H Arai; K Hamajima; I Gorai; K Nishioka; K Okuda
Journal:  Immunology       Date:  1997-09       Impact factor: 7.397

Review 3.  Immune dysregulation and CD4+ T cell loss in HIV-1 infection.

Authors:  L Meyaard; F Miedema
Journal:  Springer Semin Immunopathol       Date:  1997

4.  Mycobacterial codon optimization enhances antigen expression and virus-specific immune responses in recombinant Mycobacterium bovis bacille Calmette-Guérin expressing human immunodeficiency virus type 1 Gag.

Authors:  Masaru Kanekiyo; Kazuhiro Matsuo; Makiko Hamatake; Takaichi Hamano; Takeaki Ohsu; Sohkichi Matsumoto; Takeshi Yamada; Shudo Yamazaki; Atsuhiko Hasegawa; Naoki Yamamoto; Mitsuo Honda
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

5.  Protection of human immunodeficiency virus type 2-exposed seronegative macaques from mucosal simian immunodeficiency virus transmission.

Authors:  P Putkonen; B Mäkitalo; D Böttiger; G Biberfeld; R Thorstensson
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

6.  Type 1 and type 2 cytokine profiles in children exposed to or infected with vertically transmitted human immunodeficiency virus.

Authors:  B N Lee; J G Lu; M W Kline; M Paul; M Doyle; C Kozinetz; W T Shearer; J M Reuben
Journal:  Clin Diagn Lab Immunol       Date:  1996-09

7.  Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guérin vector candidate vaccine for human immunodeficiency virus type 1 in small animals.

Authors:  M Honda; K Matsuo; T Nakasone; Y Okamoto; H Yoshizaki; K Kitamura; W Sugiura; K Watanabe; Y Fukushima; S Haga; Y Katsura; H Tasaka; K Komuro; T Yamada; T Asano; A Yamazaki; S Yamazaki
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

8.  Induction of feline immunodeficiency virus-specific cell-mediated and humoral immune responses following immunization with a multiple antigenic peptide from the envelope V3 domain.

Authors:  J N Flynn; C A Cannon; G Reid; M A Rigby; J C Neil; O Jarrett
Journal:  Immunology       Date:  1995-06       Impact factor: 7.397

9.  Th1 cells specific for HIV-1 gag p24 are less efficient than Th0 cells in supporting HIV replication, and inhibit virus replication in Th0 cells.

Authors:  A Vyakarnam; P M Matear; S J Martin; M Wagstaff
Journal:  Immunology       Date:  1995-09       Impact factor: 7.397

Review 10.  Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen.

Authors:  M Bendinelli; M Pistello; S Lombardi; A Poli; C Garzelli; D Matteucci; L Ceccherini-Nelli; G Malvaldi; F Tozzini
Journal:  Clin Microbiol Rev       Date:  1995-01       Impact factor: 26.132
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.